Skip to main content
OpenTrials
Completed

NCT Number: NCT01265719

Long-Term Non-Interventional Latanoprost Study

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitair Ziekenhuis Antwerpen, Dienst Oftalmologie, Edegem, Belgium

Loading trial locations.

About this study

At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
  • Diagnosis of pediatric glaucoma or elevated intraocular pressure.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.

For treated subjects only:

  • Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.

For untreated subjects only:

  • Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
  • No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.

Exclusion criteria

  • Unable/unwilling to comply with protocol.
  • Pregnant or nursing females at baseline.
  • For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).

Treatment and study plan

No intervention other than routine medical care

Other

Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.

Other names: Observational

Primary outcomes

  1. Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent)

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Patients familiar with the letters of the alphabet were evaluated using Snellen visual acuity. Patients who were unable or unfamiliar with the letters of the alphabet were evaluated using charts made up of numbers, pictures (eg, Schering's Children's Eye Chart or Allen Cards), E's, or Landolt's broken rings, and other methods which were equivalent to Snellen acuity eg, HOTV testing).

Secondary outcomes

  1. Number of Participants With Clinically Meaningful Change in Refractive Error

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    The refractive error [cycloplegic where appropriate (eg, those unable to cooperate with manifest refraction)] were determined at the baseline visit and assessed at the following visits.

  2. Change From Baseline to Last Available Observation in Horizontal Corneal Diameter (by Caliper and/or Ruler)

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    The horizontal corneal diameter was measured along the horizontal meridians. Diameter was measured using either a series of transparent plates with holes of different diameters in quarter-millimeter increments or with calibrated calipers compared against a ruler. When using calipers, the corneal diameter measurement was taken from limbus to a similar point 180° away at the opposite limbus. When not examining the children with anesthesia, it was recommended to use a tape measure across the head while measuring horizontal corneal diameter by photographic method.

  3. Change From Baseline to Last Available Observation in Intraocular Pressure (IOP)

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    IOP was preferably measured using 1 of 3 applanation-contact methods: Goldmann applanation tonometry, Perkins tonometry, or TonoPen® (tonometry). iCare® rebound tonometer was also allowed if it was used consistently throughout the study.

  4. Cup-to-disc Ratio (for Assessment of Optic Nerve Changes/Structures) - Number of Participants With Clinically Significant Deterioration in Cup/Disc Ratios

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    The cup/disc ratio was recorded horizontally and vertically for each examination, and reported in 0.1 increments.

  5. Visual Field Defects - Number of Participants With Clinically Significant Deterioration of Visual Field Defects.

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    A visual field examination was performed for those patients who can cooperate automated perimetry utilizing a threshold program. All visual fields was conducted utilizing the standard white background with a Goldmann size III white stimulus. For those patients who can not perform formal visual field testing, then field to confrontation test was used for younger, non-verbal children, central, steady and maintains fixation was used.

  6. Iris Color Darkening

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Changes from baseline in iris color were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

  7. Localized Pigmentation (Nevi or Freckles) of Conjunctiva, Iris and Choroid

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Changes from baseline in localized pigmentation (nevi and freckles) of the conjunctiva, iris and choroid were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

  8. Eyelash Darkening/Thickening

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Changes from baseline in eyelash darkening/thickening/lengthening were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

  9. Change From Baseline to Last Available Observation in Length of Eyelash (by Caliper and/or Ruler)

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    The longest eyelash (mm) measured by caliper or ruler was recorded at baseline and each follow-up visit.

  10. Change From Baseline to Last Available Observation in Corneal Thickness (Pachymeter)

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Central corneal thickness was measured using a calibrated pachymeter, preferably an ultrasonic pachymeter.

  11. Conjunctival/Ocular Hyperemia

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Conjunctiva hyperemia was assessed by slit-lamp examination. When slit-lamp examination is not possible due to subject cooperation, a fixation light and 20-diopter lens (for magnification) was used to assess this parameter. Conjunctival hyperemia was assessed and graded by ophthalmologist at baseline and follow-up visits from grades 0-3 and is as follows:

    0 = None, Normal: few vessels of palpebral or bulbar conjunctiva easily observed

    • = Mild, Reddening of the palpebral or bulbar conjunctiva
    • = Moderate, Bright reddening of the palpebral or bulbar conjunctiva
    • = Severe, Deep, bright, and diffuse reddening of the palpebral or bulbar conjunctiva
  12. Number of Participants With a Change in Anterior Segment Biomicroscopy

    Time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

    Slit-lamp biomicroscopy (mounted or hand-held) without fluorescein and without dilation of the pupil was performed. When slit-lamp examination was not possible, a fixation light and 20-diopter lens (for magnification) was used. At each scheduled visit, deposition of pigment on the corneal endothelial layer or the lens capsule or any abnormalities of the lids, conjunctivae, cornea, anterior chamber, iris, or lens was examined.

  13. Number of Participants With Abnormalities in Fundoscopy Posterior Segment at Baseline

    Time frame: Evaluated at Baseline

    Fundoscopy was performed after dilation of the pupils (eg, 1 % tropicamide or cyclopentolate and 2 ½ % phenylephrine, or a clinically- appropriate dose according to the clinician's standard care of each particular patient). The examination included an evaluation of the vitreous body, retina (including the macula), and optic nerve head.

    The fundoscopy e-CRF was completed only at baseline because the investigators were required to perform slit lamp, direct or indirect ophthalmoscopy at each visit and report any AEs observed which included the vitreous, retina and optic nerve.

Sponsors and collaborators

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Industry

Registry information

Official study title

A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations

Acronym: LYNX

Important dates

Study start
2010
Primary completion
2016
Study completion
2016
First posted
Dec 23, 2010
Registry last updated
Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.